Centenial Surgical Suture Ltd has formally responded to a BSE surveillance inquiry regarding unusual price movements in its shares, alleging systematic manipulation by unknown parties through coordinated trading activities.

BSE Surveillance Inquiry Response

The company received correspondence L/SURV/ONL/PV/APJ/ 2025-2026 / 3430 dated Friday, March 13, 2026, from BSE Limited's surveillance department seeking clarification on significant price movements. Company Secretary Mahima Bathwal responded on March 17, 2026, acknowledging the unusual trading patterns and providing detailed analysis of suspected manipulative activities.

Alleged Manipulation Pattern

The company identified suspicious trading characteristics that suggest coordinated price manipulation:

• Small lot transactions: Most buyers purchasing only 1-5 shares
• Geographical spread: Buyers distributed across India to avoid surveillance detection
• Repeated investors: Same individuals appearing in multiple transactions
• Synchronized trading: Coordinated buying and selling activities
• Circuit manipulation: Use of upper/lower circuit mechanisms to control price movements

The company emphasized that these transactions appear unnatural and highly suspicious, lacking genuine commercial substance.

Trading Data Analysis

Centenial Surgical Suture provided comprehensive trading data spanning multiple periods from January 2026 to March 2026, documenting extensive buy and sell activities:

Sample Trading Activity (January 2-9, 2026)

The annexures detail hundreds of individual transactions involving resident individuals, with most transactions involving minimal share quantities that would not typically justify significant price movements.

Company's Position

The management clarified several key points in their response:

• No material announcements: The company confirmed no pending announcements or material information that could justify price movements
• No regulatory proceedings: No ongoing legal or regulatory matters affecting the business
• Clean management: Company, promoters, directors, and associates have no involvement in the alleged manipulation
• Compliance commitment: Continued adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Investigation Request

Centenial Surgical Suture formally requested BSE to:

• Conduct comprehensive investigation into the trading patterns
• Examine the genuineness of transactions between parties
• Initiate appropriate penal actions against involved broking houses and clients
• Treat the matter as an emergency to protect shareholder interests

The company expressed willingness to provide full assistance in any detailed investigation for probable violation of securities laws.

Market Impact Concerns

The alleged manipulation has created artificial price volatility without any fundamental business justification. The company noted that trading volumes during manipulation periods were extremely thin, lacking credentials to justify sharp price movements. This artificial activity potentially misleads genuine investors and affects the company's market reputation.

The response demonstrates the company's proactive approach to protecting shareholder interests and maintaining market integrity by reporting suspected manipulation to regulatory authorities.

Centenial Surgical Suture Ltd has filed a formal complaint with BSE Limited alleging unusual trading activities and price manipulation in its scrip 531308. The company has requested urgent investigation into what it describes as manipulative and unethical trading practices that have artificially influenced its share price.

Complaint Details and Timeline

The complaint, dated February 16, 2026, was signed by Company Secretary Mahima Bathwal and addressed to BSE's Investigation and Surveillance Department. The company identified suspicious trading activities during the period from February 06, 2026 to February 13, 2026, involving multiple individuals engaging in small-volume transactions.

Alleged Trading Irregularities

The company reported that several individuals were trading in unusually small quantities of 1, 2, 3, 4, and 5 equity shares during the specified period. According to the complaint, these trading patterns appeared coordinated and designed to manipulate the last traded price (LTP) of the scrip.

Key concerns raised by the company include:

• Transactions executed at prices higher than the LTP
• Circular trading patterns with no real change in beneficial ownership
• Family members trading shares between each other in small quantities
• Artificial price increases not supported by corporate announcements or business developments

Detailed Trading Data Provided

The complaint includes Annexure A, which contains comprehensive trading data for the investigation period. The data shows both selling and buying activities across multiple demat accounts, with detailed information including:

Notable sellers included individuals who disposed of 50, 49, 36, 35, and 34 shares respectively, while buyers acquired shares in quantities ranging from 1 to 75 shares. The company emphasized that these sellers had sufficient quantities in their demat accounts but chose to sell in minuscule amounts.

Regulatory Violations Alleged

Centenial Surgical Suture has alleged violations of multiple SEBI regulations, specifically citing contraventions of:

• Regulations 3(a), (b), (c), and (d) of SEBI (Prohibition of Fraudulent and Unfair Trade Practices) Regulations, 2003
• Regulation 4(1), (2), (a), and (e) of PFUTP Regulations

The company characterized these activities as "serious misconduct and manipulation to increase the price of equity shares" and requested the issuance of Show Cause Notices (SCN) against the alleged manipulators.

Company's Position and Requests

The company has categorically denied any involvement by its promoters, directors, key managerial personnel, or their immediate relatives in the alleged manipulative trading. Management stated that no corporate announcements or material business changes justified the observed price movements.

The complaint emphasizes the company's commitment to protecting shareholder interests and maintaining market integrity. Management has offered full cooperation for any detailed investigation and requested that the matter be treated as an emergency requiring priority attention from regulatory authorities.